The framework has had a lukewarm reaction, with trade association EFPIA saying the policies are “not strong enough”.

Propelled by a flurry of dealmaking late in the year, 2025 M&A ended on a strong note, with high activity expected to ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

Zealand Pharma and OTR Therapeutics are to collaborate to discover and develop therapies for several targets in metabolic diseases.